Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Progressive Corp (PGR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Progressive Corp — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Progressive Corp trades at $226 (market cap $131.91B). The key difference: Progressive Corp is far larger — about 16.4× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Progressive Corp pays a 6.13% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | PGR | |
|---|---|---|
Market Cap | $8.04B | $131.91B |
Sector | Health | Financials |
52-Week High | $339.75 | $252.68 |
52-Week Low | $241.71 | $190.40 |
Enterprise Value | $7.85B | $140.14B |
Dividend Yield | — | 6.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Progressive (PGR) trades at $234.48, up 1.63% today, near its consensus price target of $240.89. The stock shows strong fundamentals with revenue growth from $49.6B in 2022 to $87.6B in 2025 and a net income margin of 12.93%. Technical indicators are bullish, with the price above key moving averages. Recent news highlights focus on Q2 2026 earnings expectations due July 15, 2026.
Outlook is positive given earnings growth and analyst buy ratings, but risks include potential earnings misses and competitive pressures. The stock offers value with a P/E of 11.93, below industry averages, supporting a bullish view for long-term investors despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Progressive Corp
Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →
